About MET expression and other biomarkers in non-small cell lung cancer

Sterlacci W, Fiegl M, Gugger M, Budendorf L, Savic S, Tzankov A (2017) MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. Virchows Arch 471:49–55 Spigel DR, Ervin TJ, Ramlau A, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel RH, Phan SC, Peterson AC (2013) Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105–4114 Drilon A, Cappuzzo F, Si O, Camidge DR (2017) Targeting MET in lung cancer: will expectations finally be MET? J Thor Oncol 12:15–26 Vassal G, Ledeley MC, Tournigand C, Aparicio T, Ray-Coquard I, Taillandier L, Escudier B, You B, Goncalves A, Lombard Bohas B, Seitz JF, André T, Merlio JP, Arnould L, Ferretti G, Menu Y, Mortier T, Lonchamp E, Mahier-Ait Oukhatar C, Moro-Sibilot D (2015) Activity of crizotinib in relapsed MET amplified malignancies: results of the French AcSé program. 2015 ASCO Conference. www.unicancer.fr/sites/default/files/PosterUNICANCER_TUMEUR-AMPLIFIED_ASCO%202015.pdf